Key Highlights

  • Novocure closed at USD 17.85 on June 17, up 2.06%, with volume near 1.22 million shares.
  • NVCR traded at USD 15.73 pre-market on June 18, down 11.89% from the prior close.
  • The TRIDENT trial missed its primary endpoint, although both treatment arms showed durable survival and no new safety signals.

Why the Stock Moved

Novocure Limited (NASDAQ:NVCR) fell 11.89% in June 18 pre-market trading to USD 15.73 after closing at USD 17.85 on June 17.

The decline followed topline results from the Phase 3 TRIDENT trial in newly diagnosed glioblastoma. The study evaluated whether starting Tumor Treating Fields therapy at the beginning of chemoradiation could improve overall survival compared with starting treatment during the maintenance phase.

The trial did not meet its primary endpoint. Median overall survival was 17.7 months in the early-start group and 17.5 months in the maintenance-start group. The hazard ratio was 0.953, with a p-value of 0.519, meaning the difference was not statistically significant.

The result weakened the case for expanding TTFields use into an earlier treatment setting for the broad trial population.

What the Trial Still Showed

The data were not entirely negative. Both treatment groups showed durable survival outcomes, and no new safety signals were identified.

One-year survival was 70.9% in the early-start arm and 72.0% in the maintenance-start arm. At three years, survival was 22.5% for early treatment and 18.4% for maintenance treatment.

Management also noted that earlier treatment was feasible and well tolerated. Novocure plans to present further analyses at the ASTRO 2026 Annual Meeting, where investors will look for evidence of benefit in patient subgroups.

However, subgroup signals are unlikely to carry the same commercial weight as a successful primary endpoint.

Company Background

Novocure is an oncology company focused on Tumor Treating Fields, an electric-field-based treatment designed to disrupt cancer cell division.

Its products are approved in certain markets for glioblastoma, non-small cell lung cancer, pancreatic cancer and mesothelioma.

The company’s investment case depends on expanding TTFields into additional tumour types and earlier stages of treatment. Large Phase 3 trials are therefore central to future revenue growth and valuation.

Valuation and Clinical Risk

At the June 17 close, Novocure had a market capitalisation of about USD 2.07 billion. The company reported EPS of approximately negative USD 1.53 and does not have a meaningful trailing P/E ratio.

The stock’s 52-week range of USD 9.82 to USD 18.92 shows that investors had recently priced in improving clinical and commercial expectations.

The TRIDENT miss introduces uncertainty around one of the company’s most important expansion opportunities. Although the result does not undermine existing approved uses of TTFields, it may reduce assumptions for incremental glioblastoma adoption.

Clinical-stage and oncology stocks can reprice sharply when pivotal studies fail because projected future revenue is often concentrated around a small number of programmes.

Liquidity and Trading Dynamics

NVCR traded about 1.22 million shares on June 17. The sharp pre-market decline indicates an immediate reassessment of clinical value, but pre-market trading can remain volatile because liquidity is thinner than during the regular session.

Regular-session volume and management commentary will help determine whether the initial decline deepens or stabilises.

What Investors Are Watching Next

Investors will focus on detailed TRIDENT subgroup analyses, secondary endpoints and the upcoming ASTRO presentation.

Markets will also monitor commercial performance in approved indications, other TTFields trials and whether management changes its development strategy for newly diagnosed glioblastoma.

The company’s ability to identify a clinically meaningful subgroup could preserve some strategic value, but further evidence will be required.

Conclusion

Novocure’s 11.89% pre-market decline reflects disappointment that TRIDENT failed to show a statistically significant survival advantage from starting TTFields earlier.

The study confirmed safety and durable outcomes in both arms, but the missed primary endpoint limits the immediate commercial implications. The next valuation test will come from detailed subgroup data and the broader pipeline.